T-cell phenotypes associated with effective CAR T-cell therapy in postinduction vs relapsed multiple myeloma

• Alfred L. Garfall,
• Ehren K. Dancy,
• Adam D. Cohen,
• Wei-Ting Hwang,
• Joseph A. Fraietta,
• Megan M. Davis,
• Bruce L. Levine,
• Don L. Siegel,
• Edward A. Stadtmauer,
• Dan T. Vogl,
• Adam Waxman,
• Aaron P. Rapoport,
• Michael C. Milone,
• Carl H. June,
• J. Joseph Melenhorst

Affiliations

Alfred L. Garfall

Division of Hematology-Oncology, Department of Medicine, Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA; Alfred L. Garfall, Perelman Center for Advanced Medicine, 12th Floor, South Pavilion Extension, 3400 Civic Center Blvd, Philadelphia, PA 19104;

Ehren K. Dancy

Department of Medicine, Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA

Adam D. Cohen

Division of Hematology-Oncology, Department of Medicine, Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA

Wei-Ting Hwang

Department of Biostatistics, Epidemiology and Informatics, Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA

Joseph A. Fraietta

Department of Microbiology, Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA; Department of Pathology and Laboratory Medicine, Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA; Center for Cellular Immunotherapies, Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA

Megan M. Davis

Department of Pathology and Laboratory Medicine, Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA; Center for Cellular Immunotherapies, Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA

Bruce L. Levine

Department of Pathology and Laboratory Medicine, Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA; Center for Cellular Immunotherapies, Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA

Don L. Siegel

Department of Pathology and Laboratory Medicine, Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA; Center for Cellular Immunotherapies, Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA

Edward A. Stadtmauer

Division of Hematology-Oncology, Department of Medicine, Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA

Dan T. Vogl

Division of Hematology-Oncology, Department of Medicine, Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA

Adam Waxman

Division of Hematology-Oncology, Department of Medicine, Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA

Aaron P. Rapoport

University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore, MD

Michael C. Milone

Department of Pathology and Laboratory Medicine, Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA; Center for Cellular Immunotherapies, Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA

Carl H. June

Department of Pathology and Laboratory Medicine, Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA; Center for Cellular Immunotherapies, Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA

J. Joseph Melenhorst

Department of Pathology and Laboratory Medicine, Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA; Center for Cellular Immunotherapies, Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA